We were invited to participate in a new clinical trial conducted by the pharmaceutical company Bayer: a new anticoagulant for the treatment of atrial fibrillation.
We were invited to participate in a new clinical trial conducted by the pharmaceutical company Bayer: a new anticoagulant for the treatment of atrial fibrillation.